Trial Profile
MUC-1 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Pancreatic Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2019
Price :
$35
*
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Apr 2019 Planned initiation date changed from 11 Jul 2018 to 8 Aug 2018.
- 16 Aug 2018 New trial record